Abstract
We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61) weeks. Toxicity was mild and mainly hematologic.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Bendamustine Hydrochloride
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / epidemiology
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / epidemiology
-
Nitrogen Mustard Compounds / administration & dosage*
Substances
-
Antineoplastic Agents
-
Nitrogen Mustard Compounds
-
Bendamustine Hydrochloride